{"product_id":"zimvie-five-forces-analysis","title":"ZimVie Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZimVie faces moderate buyer power and supplier leverage, while rivalry among established medtech firms and regulatory barriers shape its strategic landscape; substitutes and new entrants pose manageable but evolving threats tied to innovation and cost pressures. This brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore ZimVie’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie depends on high‑purity titanium, medical ceramics, and specialized polymers for implants; only about 15–25 vetted global suppliers meet FDA\/ISO medical‑grade specs, concentrating supply and giving vendors pricing leverage. In 2024 ZimVie spent roughly $220M on direct materials, and a 10–15% price hike from suppliers could cut gross margin by ~250–350 basis points, since substitutes would risk regulatory noncompliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrict Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers in medtech must follow strict quality systems like ISO 13485; noncompliance risks regulatory fines and device recalls—global medtech recall costs averaged $1.2B annually in 2023. Any supplier change forces ZimVie into validation and re‑certification (FDA 21 CFR 820), often taking 6–12 months and $0.5–2M in direct costs, so high switching costs and long qualification times boost incumbent suppliers’ bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Manufacturing Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain components for ZimVie’s digital dentistry and surgical guide systems rely on third-party proprietary tech; when suppliers hold unique patents or niche expertise, ZimVie faces limited alternative sourcing and higher switching costs. In 2024, proprietary-component suppliers in medtech raised prices ~4–6% on average, letting suppliers sustain firm pricing and push lead times; delays can extend product time-to-market by 8–12 weeks, affecting revenue recognition and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas of late geopolitical shifts and regional trade rules have increased transit times for medical components by raised cross tariffs key inputs up to squeezing zimvie supply chain.\u003e\n\u003cpsuppliers face higher energy and specialized transport costs year they are passing a large share of these increases to device makers protect margins.\u003e\n\u003cp\u003eThis raises input-cost volatility for ZimVie and increases procurement risk and NRE (non‑recurring engineering) pass‑throughs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTransit times +12% (2025)\u003c\/li\u003e\n\u003cli\u003eTariffs up to +4% (late 2025)\u003c\/li\u003e\n\u003cli\u003eSupplier energy\/transport cost rise 18–25%\u003c\/li\u003e\n\u003cli\u003eHigher input volatility → procurement risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/psuppliers\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Vertical Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimVie keeps core manufacturing in-house but relies on external suppliers for key sub-assemblies and raw feedstock, leaving some product lines not fully vertically integrated.\u003c\/p\u003e\n\u003cp\u003eThat dependence makes ZimVie vulnerable to its largest vendors’ pricing and capacity choices; in 2024 roughly 22% of COGS traced to three supplier clusters per company filings.\u003c\/p\u003e\n\u003cp\u003eTo mitigate risk ZimVie signs multi-year supply agreements that prioritize supplier stability, often constraining short-term cost reductions.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~22% of COGS from top supplier clusters (2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts common\u003c\/li\u003e\n\u003cli\u003ePartial vertical integration = strategic exposure\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier power risks: $220M spend, 15–25 vendors, 10–15% shocks → −250–350bps GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong leverage: 15–25 qualified medical‑grade vendors, ~22% of 2024 COGS tied to top clusters, and $220M direct‑materials spend—10–15% input price shocks cut gross margin ~250–350 bps. Long FDA\/ISO validation (6–12 months; $0.5–2M) and proprietary parts raise switching costs; 2024–25 transport +12%, tariffs +4%, supplier energy\/transport +18–25% increase input volatility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003e15–25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 direct materials\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop supplier COGS share (2024)\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice shock impact\u003c\/td\u003e\n\u003ctd\u003e10–15% → −250–350 bps GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation time\/cost\u003c\/td\u003e\n\u003ctd\u003e6–12 months; $0.5–2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransit change (2025)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariffs (late 2025)\u003c\/td\u003e\n\u003ctd\u003eup to +4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier energy\/transport rise\u003c\/td\u003e\n\u003ctd\u003e18–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for ZimVie that uncovers competitive drivers, supplier and buyer power, substitution risks, and entry barriers, with strategic commentary on emerging threats and market defenses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA one-sheet Porter's Five Forces summary for ZimVie that highlights competitive pressures and acquisition risks—ideal for rapid strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Dental Service Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rise of large Dental Service Organizations (DSOs) like Heartland Dental and Smile Brands, which together manage over 6,000 U.S. clinics by 2024, shifts bargaining power away from solo dentists toward corporate buyers.\u003c\/p\u003e\n\u003cp\u003eThese DSOs leverage combined annual purchasing — often tens to hundreds of millions per group — to demand double-digit volume discounts and extended payment terms.\u003c\/p\u003e\n\u003cp\u003eZimVie must negotiate with sophisticated procurement teams that routinely pit manufacturers against each other, pressuring margins and forcing bundled pricing or rebates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Elective Procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany dental implant and aesthetic procedures are elective and often paid out-of-pocket, so clinicians and labs are highly price-sensitive to component costs to keep patient prices competitive; in 2024 US dental out-of-pocket spending reached about $61.5 billion, heightening cost pressure. ZimVie must justify premium pricing with superior clinical outcomes or risk losing share to lower-cost competitors—global implant price compression averaged ~3–5% annually in 2023–24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of Alternative Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe dental implant market is highly fragmented: over 200 global and regional suppliers compete, with low-cost manufacturers driving price pressure—global implant market grew 6.3% CAGR to $5.8B in 2024. Customers can switch brands for better price-performance, raising churn risk; surveys show 38% of clinics cite cost as primary switching reason. This abundance forces ZimVie to invest in superior customer service and technical support to protect loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGPOs drive down prices for spinal and dental surgical kits via competitive bidding, and in 2024 GPO-negotiated contracts covered roughly 70% of U.S. hospital supply spend, forcing ZimVie to accept tighter margins.\u003c\/p\u003e\n\u003cp\u003eParticipation in GPO networks is often mandatory for market access, so ZimVie loses pricing autonomy and faces contract-driven volume but reduced ASPs (average selling prices) and margin pressure.\u003c\/p\u003e\n\u003cp\u003eWhat this hides: if a GPO contract wins 12–18 month exclusivity, ZimVie may gain volume but see gross margins fall by 3–7 percentage points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% U.S. hospital spend under GPOs in 2024\u003c\/li\u003e\n\u003cli\u003eMandatory network access limits price setting\u003c\/li\u003e\n\u003cli\u003eContract exclusivity can cut margins 3–7 ppt\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInformed Clinical Decision Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern dental surgeons access peer-reviewed meta-analyses showing implant survival rates of 95–98% at 5 years, so purchase decisions hinge on hard clinical metrics not ads.\u003c\/p\u003e\n\u003cp\u003eThat transparency forces ZimVie to fund and publish trials—ZimVie reported $75m R\u0026amp;D in 2024—else clinicians switch to competitors with better evidence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95–98% 5‑yr implant survival\u003c\/li\u003e\n\u003cli\u003eZimVie R\u0026amp;D ~$75m in 2024\u003c\/li\u003e\n\u003cli\u003eClinicians favor peer‑reviewed data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidated buyers cut ASPs; R\u0026amp;D \u0026amp; evidence key as cost drives 38% clinic switches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge DSOs and GPOs concentrate buying power, pushing down ASPs and forcing volume discounts; ~6,000 DSO clinics (Heartland, Smile Brands) and ~70% of US hospital spend under GPOs in 2024 amplify this pressure.\u003c\/p\u003e\n\u003cp\u003eClinicians demand peer‑reviewed evidence (5‑yr implant survival 95–98%), making R\u0026amp;D ($75m in 2024) and service critical to retain share; switching driven mainly by cost (38% of clinics).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDSO-managed clinics (US)\u003c\/td\u003e\n\u003ctd\u003e~6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS hospital spend via GPOs\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5‑yr implant survival\u003c\/td\u003e\n\u003ctd\u003e95–98%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZimVie R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$75m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinics citing cost as switch reason\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eZimVie Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ZimVie Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the part of the full, professionally formatted version you’ll get—ready for download and use the moment you buy.\u003c\/p\u003e\n\u003cp\u003eNo mockups or samples: what you see is the final deliverable and will be available to you instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747437293945,"sku":"zimvie-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zimvie-five-forces-analysis.png?v=1772198464","url":"https:\/\/growthsharematrix.com\/products\/zimvie-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}